<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43719">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02137525</url>
  </required_header>
  <id_info>
    <org_study_id>INS-14-022</org_study_id>
    <nct_id>NCT02137525</nct_id>
  </id_info>
  <brief_title>Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute Pain</brief_title>
  <official_title>A Randomized, Multicenter, Double-Blind, Double Dummy, Active Comparator, Dose-Ranging Study to Explore the Efficacy of SUBSYS® in Emergency Department Patients With Acute Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>INSYS Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>INSYS Therapeutics Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore effectiveness of three doses of fentanyl sublingual spray against an
      active comparator in emergency department (ED) patients with acute pain.

      After screening, eligible participants will participate in a treatment period (up to 2
      hours) and a post-treatment evaluation period (up to 4 hours or discharge from the ED).
      Open-label standard of care rescue medication for pain can be given at any time during the
      study period, based on clinical judgment of the treating physician.

      Adverse events will be collected for five days after initial enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of participants requiring additional doses of randomized pain medication</measure>
    <time_frame>at 30 minutes after initial treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants requiring additional doses of randomized pain medication at secondary time points</measure>
    <time_frame>within 120 minutes after initial treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scale (VAS) Summed Pain Intensity Difference (SPID) calculated as Area under the Curve (AUC) every 30 minutes</measure>
    <time_frame>from baseline through 120 minutes after the initial dose of investigational product</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Investigational Product (IP) administrations</measure>
    <time_frame>within 120 minutes after initial treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of pain relief (in minutes) using the stopwatch method</measure>
    <time_frame>within 120 minutes after first treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Richmond Agitation Sedation Scale (RASS) score</measure>
    <time_frame>within 120 minutes after first treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants requiring rescue medication</measure>
    <time_frame>during the 5-day study period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until rescue medication was required</measure>
    <time_frame>during the 5-day study period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants experiencing a treatment-related adverse event</measure>
    <time_frame>during the 5-day study period</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with clinically significant changes in vital signs</measure>
    <time_frame>during the 5-day study period</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>Morphine 6 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo Sublingual Spray (PSS) + Intravenous Morphine (IVM 6 mg), every 30 minutes for two hours as needed (or until rescue), maximum exposure morphine 30 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl 100 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 100 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 500 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl 200 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 200 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 1000 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl 400 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 400 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 2000 µg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine 6 mg</intervention_name>
    <description>Intravenous infusion - delivering morphine 6 mg</description>
    <arm_group_label>Morphine 6 mg</arm_group_label>
    <other_name>IVM 6 mg</other_name>
    <other_name>Standard of Care</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl 100 µg</intervention_name>
    <description>Fentanyl sublingual spray  - single unit delivering 100 µg fentanyl</description>
    <arm_group_label>Fentanyl 100 µg</arm_group_label>
    <other_name>FSS 100 µg</other_name>
    <other_name>SUBSYS®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl 200 µg</intervention_name>
    <description>Fentanyl sublingual spray - single unit delivering 200 µg fentanyl</description>
    <arm_group_label>Fentanyl 200 µg</arm_group_label>
    <other_name>FSS 200 µg</other_name>
    <other_name>SUBSYS®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl 400 µg</intervention_name>
    <description>Fentanyl sublingual spray - single unit delivering 400 µg fentanyl</description>
    <arm_group_label>Fentanyl 400 µg</arm_group_label>
    <other_name>FSS 400 µg</other_name>
    <other_name>SUBSYS®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Sublingual Spray</intervention_name>
    <description>Matching sublingual spray - single unit delivering 0 µg fentanyl</description>
    <arm_group_label>Morphine 6 mg</arm_group_label>
    <other_name>PSS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Placebo</intervention_name>
    <description>Matching intravenous infusion - delivering 0 mg morphine</description>
    <arm_group_label>Fentanyl 100 µg</arm_group_label>
    <arm_group_label>Fentanyl 200 µg</arm_group_label>
    <arm_group_label>Fentanyl 400 µg</arm_group_label>
    <other_name>IVP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is able to understand the language in which the study is being conducted and has
             provided meaningful written informed consent for the study

          -  Has an acute painful condition requiring parenteral analgesia as deemed necessary by
             the treating physician or physician extender

          -  Has a pain score within protocol-specified parameters

        Exclusion Criteria:

          -  Has allergy to fentanyl or morphine

          -  Has oxygen-dependent conditions or oxygen saturation &lt;95%

          -  Has planned or recent drug use outside protocol-specified parameters

          -  Has any condition that, in the principal investigator's opinion, would place the
             patient at risk or influence the conduct of the study or interpretation of results
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Collins, MD, MSc, FACC, FAHA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giovanni DeCastro</last_name>
    <role>Study Director</role>
    <affiliation>INSYS Therapeutics Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa Ortiz Alvidrez</last_name>
    <phone>1-512.351.9805</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sean Collins, MD, MSc, FACC, FAHA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>May 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
